Polyrizon Ltd. announced today the signing of a non-binding Letter of Intent (LOI) with a biotech company specializing in psychedelic-derived therapeutics. The agreement aims to develop a novel intranasal formulation for psychedelic-based treatment applications.
This collaboration seeks to leverage Polyrizon’s proprietary platform to optimize the delivery of innovative psychedelic treatments, potentially enhancing bioavailability, efficacy, and patient accessibility. Polyrizon will lead the formulation's development, utilizing its mucoadhesive drug delivery technology.
Under the terms of the LOI, the psychedelic company will fund the research and development process, including feasibility studies. If successful, the companies intend to negotiate a definitive agreement, with Polyrizon slated to receive royalty payments for any future commercialization of the product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.